Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw a large growth in short interest in February. As of February 27th, there was short interest totaling 11,389 shares, a growth of 25.6% from the February 12th total of 9,071 shares. Based on an average daily volume of 20,191 shares, the short-interest ratio is currently 0.6 days. Approximately 0.0% of the company’s stock are short sold. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 20,191 shares, the short-interest ratio is currently 0.6 days.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group in the second quarter worth $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group in the 4th quarter valued at $224,000. Millennium Management LLC bought a new position in Pharming Group in the 4th quarter worth $360,000. Finally, NewEdge Advisors LLC lifted its position in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the last quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Stock Up 6.3%

Shares of PHAR traded up $0.92 during trading hours on Monday, hitting $15.43. 87,723 shares of the company were exchanged, compared to its average volume of 30,636. The company has a market cap of $1.08 billion, a PE ratio of 1,543.00 and a beta of 0.04. The firm’s 50 day moving average is $17.21 and its 200-day moving average is $16.09. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. The company had revenue of $106.50 million during the quarter, compared to the consensus estimate of $111.76 million. On average, equities research analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings cut Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research report on Friday. Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday. HC Wainwright set a $37.00 target price on shares of Pharming Group and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $39.00.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.